Company News - Press Releases - Events - Publications

Bicoll and the European Molecular Biology Laboratory (EMBL) announce results of their joint research project on the identification of aurora kinase inhibitors

Munich (Germany), Heidelberg (Germany) – June 22, 2010 – BICOLL GmbH, a biopharmaceutical
drug discovery company specializing in high-tech natural product chemistry to identify novel small
molecules for drug discovery and related innovative fields and EMBL, the renowned international and
inter-governmental research organisation, focusing on molecular biology and biophysics, today
announce the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases.

Questions? Get in touch!

We would love talking to you:

Bicoll GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
+49 (0)89 820 106 30

This Site uses cookies, which could include third-party cookies, to ensure its technical functioning and which may contain tracking information about visitors. By continuing to browse this site you agree to our use of cookies. If you want to learn more about our Privacy Policy click here.